ProCE Banner Activity

Selecting First-line and Second-line Therapy in EGFR Mutation–Positive NSCLC

Slideset Download
Download this slideset to get up to date on the latest first-line and second-line clinical data in the setting of EGFR mutation–positive NSCLC.

Released: March 25, 2019

Expiration: March 23, 2020

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California